Clearside Biomedical

Clearside Biomedical FCF/Debt

Delisted

The Free Cash Flow to Debt Ratio of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -1,331.31 %. In the previous year, Free Cash Flow to Debt Ratio was -526.21 % — a change of 153.00% (lower).

FCF/Debt

-1,331.31 %

YoY

153.00%

Last updated:

Free Cash Flow to Debt Ratio of Clearside Biomedical is 2020 -1,331.31 % . Free Cash Flow to Debt Ratio of Clearside Biomedical was 2019 -526.21 % . It decreases by 153.00% lower compared to the previous year.

The Clearside Biomedical FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2015
-232.94 USD
Jan 1, 2016
-299.21 USD
Jan 1, 2017
-641.57 USD
Jan 1, 2018
-794.49 USD
Jan 1, 2019
-526.21 USD
Jan 1, 2020
-1,331.31 USD
The Clearside Biomedical FCF/Debt history
YEARFCF/DebtYoY
-1,331.31 %+153.00%
-526.21 %-33.77%
-794.49 %+23.83%
-641.57 %+114.42%
-299.21 %+28.45%
-232.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Free Cash Flow to Debt Ratio of Clearside Biomedical is -1,331.31 % in 2020.

Free Cash Flow to Debt Ratio of Clearside Biomedical changed from -526.21 % to -1,331.31 %, representing a 153.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Clearside Biomedical

All Key Metrics — Clearside Biomedical